CSL to test Horizon 2 plasma process
CSL Limited (ASX:CSL) will conduct clinical trials to confirm the efficacy and safety of immunoglobulin produced using its Horizon 2 next‑generation plasma manufacturing process, which it describes as yield‑enhancing technology.










